Yiyuan Ding
Senior Principal Scientist Bristol Myers Squibb
Seminars
Wednesday 29th April 2026
Platform Characterization & Risk Assessment of a Payload–Linker Related Variant in ADCs
1:30 pm
- Implement a platform analytical strategy using orthogonal methods to structurally characterize a recurring payload-linker, enabling proactive risk assessment and establishing a platformwide control strategy
- Conduct forced degradation studies and spiking experiments to model the variant’s behavior to quantify the kinetic formation rate of the variant and provide critical data to justify setting appropriate specification limits
Thursday 30th April 2026
Panel Discussion: Measuring Multi-Modal Function in a Complex Biological System to Create Potency Assay of the Future to Recapitulate the Tumor Microenvironment & Predict Clinical Efficacy In Vivo:
11:00 am
Exploring the future of potency, where assays must mimic the tumor microenvironment and measure integrated functions beyond cytotoxicity. This panel will debate the practical limits of complexity, the role of surrogate assays, and how to validate a “systems biology” approach to potency.
Join a strategic discussion on building the agile ADC development organization of the future by:
- Debate how complex a potency assay should become to feasibly develop co-culture assays incorporating immune cells and stromal components to reflect the in vivo mechanism of action
- Explore the potential for non-cell-based binding assays, combined with AI models to serve as validated potency methods, reducing variability and resource strain while linking clinical efficacy
- Define the line between necessary scientific rigor and impractical method proliferation for dual-mechanism ADCs, to understand the minimum number of assays needed to ensure product quality
